Xenetic Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Xenetic Biosciences reports increased royalty revenue in Q2 2026 but continues to face operational losses, while undergoing a strategic review process that may lead to significant corporate changes.
NASDAQ
Xenetic Biosciences reported increased royalty revenue but a wider net loss for Q3 2025, driven by higher research and development expenses and legal costs, while initiating a strategic review.
NASDAQ
Xenetic Biosciences reported a reduced net loss in Q2 2025, driven by lower operating expenses, as it continues to advance its DNase immune-oncology program.
NASDAQ
10-Q: Xenetic Biosciences Reports First Quarter 2025 Financial Results, Cites Progress in DNase Technology
Xenetic Biosciences reports increased royalty revenue and reduced operating expenses in Q1 2025, while continuing to advance its DNase technology for cancer treatment.
NASDAQ
Xenetic Biosciences reported its Q3 2024 financial results, highlighting a focus on advancing its DNase platform for cancer treatment and ongoing royalty revenue from its PolyXen technology.
NASDAQ
Xenetic Biosciences' second quarter 2024 results show an increase in royalty revenue but also a net loss, with a focus on advancing their DNase platform.
NASDAQ
Xenetic Biosciences reported a net loss of $1.2 million for the first quarter of 2024, while advancing its DNase platform for cancer treatment.